Pharmacogenomic Testing Service Fee
Other
≈ ¥800-2500
(≈ $115-360)
3 day
Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer
Description
Estimated cost for Pharmacogenomic Testing Service Fee at general public hospitals in China is about ¥560-2000, and at Grade 3A hospitals about ¥800-2500, varying by hospital tier and region.
Main Uses
Pharmacogenomic medication guidance service supports precision prescribing by identifying genetic variants affecting drug metabolism, transport, or targets. Primary uses include: optimizing drug selection (e.g., avoiding clopidogrel in CYP2C19 poor metabolizers); individualizing dosing (e.g., warfarin dosing guided by VKORC1/CYP2C9); predicting risk of adverse drug reactions (e.g., HLA-B*15:02-associated carbamazepine-induced SJS/TEN); informing therapeutic switching (e.g., SSRIs based on CYP2D6/CYP2C19 status); and supporting clinical decision-making in psychiatry, cardiology, oncology, and pain management per evidence-based guidelines (CPIC, FDA PGx biomarker labels).
Normal Range
Not applicable — Pharmacogenomic testing is qualitative or semi-quantitative; it does not yield numerical 'values' with a universal normal range. Instead, results are reported as genotype/allele calls (e.g., CYP2C19*1/*2), predicted phenotype (e.g., Poor Metabolizer, Normal Metabolizer), or clinical interpretation (e.g., 'Use alternative drug' or 'Reduce dose'). Reference standards depend on the specific gene-drug pair (e.g., CYP2C19 for clopidogrel; SLCO1B1 for simvastatin) and are defined by CPIC (Clinical Pharmacogenetics Implementation Consortium) or DPWG (Dutch Pharmacogenetics Working Group) guidelines.
Low Values - Possible Causes
N/A — 'Low value' is a misnomer for pharmacogenomic testing, as it does not measure analyte concentration. Apparent 'low' interpretations (e.g., reduced enzyme activity) stem from genetic variants: 1) Presence of loss-of-function alleles (e.g., CYP2C19*2 or *3); 2) Homozygous or compound heterozygous variant genotypes; 3) Gene deletions or copy number variants (e.g., CYP2D6 deletion); 4) Rare promoter variants reducing transcription; 5) Technical limitations (e.g., poor DNA quality or assay failure leading to inconclusive/missing calls).
High Values - Possible Causes
N/A — 'High value' is not applicable in standard pharmacogenomic reporting. Increased functional activity is inferred from genotypes: 1) Presence of gain-of-function alleles (e.g., CYP2D6*1xN or *2xN duplications); 2) Ultrarapid metabolizer genotype (e.g., CYP2D6 gene duplication + functional alleles); 3) Wild-type homozygous genotype (*1/*1) for genes where *1 denotes full function; 4) Absence of known loss-of-function variants; 5) Technical artifacts (e.g., allele dropout in one primer site causing false homozygous wild-type call).